News Release 

Over 70 leaders in aging and longevity to present their latest research at the 8th ARDD

Speakers revealed for the 8th Aging Research & Drug Discovery Meeting 2021

Deep Longevity Ltd

Scientific Meeting Announcement

IMAGE

IMAGE: The ARDD Meeting 2021 will be hosted on August 31 - September 3, 2021 view more 

Credit: Insilico Medicine Hong Kong Limited

21st of April, Wednesday, 2021, the Scheibye-Knudsen Lab, University of Copenhagen and Deep Longevity are excited to reveal the speakers for the 8th Aging Research & Drug Discovery Meeting, the largest scientific academic, and industry conference that will transpire on August 31 - September 3, 2021, on-site at the Ceremonial Hall, University of Copenhagen, and online.

According to the United Nations, the proportion of people aged over 65 now outnumber children younger than 5. The enormous growth in the elderly population is posing a significant healthcare challenge to societies worldwide most evident from the ongoing Covid-19 pandemic. New sweeping interventions for reducing age-associated morbidities and frailty will undoubtedly be a key to reduce the health- and socioeconomic challenges that come with an aging society. This year we have an incredibly exciting program with global thought-leaders sharing their latest insights into aging and how we target the aging process ensuring everyone lives a healthier and longer life.

"With the pandemic that has raged across the world slowly becoming manageable due to vaccines we decided to host the ARDD2021 conference in person at the University of Copenhagen. We are extremely excited about the program and the possibility of meeting friends and colleagues outside of zoom. This year we are maintaining our focus on young scientists who will be the future of our field and we have a large amount of speaker slots for these rising stars." said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.

"The 8th ARDD Meeting 2021 organized by the Scheibye-Knudsen lab will be supported by the top leaders in aging research. It will have a fresh program featuring some of the most prominent scientists and industry players in AI, drug discovery, ageing, and longevity research covering the theory, applications and convergence of these exciting areas." said Alex Zhavoronkov, Ph.D Founder, and CEO of Insilico Medicine.

###

For further information, images or interviews, please contact: ardd@insilico.com

About Scheibye-Knudsen Lab

In the Scheibye-Knudsen lab we use in silico, in vitro and in vivo models to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.

About Deep Longevity

Deep Longevity has been acquired by Regent Pacific (SEHK:0575.HK), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers. https://deeplongevity.com/

About Regent Pacific (SEHK:0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.

https://www.regentpac.com/

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.